maintain fve follow share
remain under-valued pipelin progress
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
methodolog valu compani
myelofibrosi drug jakafi strong sale growth
fourth quarter sale million
repres growth almost billion
year growth slightli beat expect
full-year stronger revenu guidanc
line assumpt slightli
rais long-term assumpt expens
also boost probabl approv sever mid-
late-stag pipelin program expect
signific chang fair valu estim firm
narrow moat support jakafi domin
posit moat trend expand jakafi approv
grow late-stag pipelin billion cash
expect firm could use add late-stag
fda review jakafi steroid-refractori graft-versus-
host diseas delay three month
approv expect may signific
addit data gvhd later year
potenti expand steroid-nav patient could
add elig patient jakafi next-
steroid-nav patient itacitinib second half
well addit ruxolitinib jakafi trial acut
pemigatinib
second-lin
cholangiocarcinoma third quarter also enter
pivot studi first-lin cholangiocarcinoma first-lin
bladder cancer year well pan-tumor trial fgf/
cream phase atop dermat data
enter phase vitiligo phase data expect year
olumi also recent met primari endpoint two atop
dermat studi royalti partner lilli
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer
partner novarti market drug includ rheumatoid
arthriti treatment olumi licens oncolog drug
iclusig chronic myeloid leukemia pipelin includ broad array
oncolog autoimmun program includ next-gener jak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
approv indic rheumatoid arthriti begin
ramp
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
